Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 11;11(4):826.
doi: 10.3390/vaccines11040826.

Comparison of Biological, Pharmacological Characteristics, Indications, Contraindications, Efficacy, and Adverse Effects of Inactivated Whole-Virus COVID-19 Vaccines Sinopharm, CoronaVac, and Covaxin: An Observational Study

Sultan Ayoub Meo  1 , Riham A ElToukhy  2 , Anusha Sultan Meo  3 , David C Klonoff  4
Affiliations

Comparison of Biological, Pharmacological Characteristics, Indications, Contraindications, Efficacy, and Adverse Effects of Inactivated Whole-Virus COVID-19 Vaccines Sinopharm, CoronaVac, and Covaxin: An Observational Study

Sultan Ayoub Meo et al. Vaccines (Basel). .

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging viral zoonotic illness that has developed a distinctive and threatening situation globally. Worldwide, many vaccines were introduced to fight against the COVID-19 pandemic. The present study aims to compare the bio-pharmacological characteristics, indications, contraindications, efficacy, and adverse effects of inactivated whole-virus COVID-19 vaccines, Sinopharm, CoronaVac, and Covaxin. Initially, 262 documents and 6 international organizations were selected. Finally, 41 articles, fact sheets, and international organizations were included. The data were recorded from the World Health Organization (WHO), Food and Drug Administration (FDA) USA, Web of Science, PubMed, EMBASE, and Scopus. The results demonstrated that these three inactivated whole-virus COVID-19 vaccines, Sinopharm, CoronaVac, and Covaxin, received emergency approval from the FDA/WHO, and all three of these vaccines are beneficial for the prevention of the COVID-19 pandemic. The Sinopharm vaccine has been recommended during pregnancy and for people of all age groups, and the CoronaVac and Covaxin vaccines are recommended for people over 18 years of age and older. These three vaccines have recommended intramuscular doses of 0.5 mL each, with a 3-4 week interval. These three vaccines can be stored in a refrigerator at +2 to +8 °C. The common adverse effects of these vaccines are pain at the injection site, redness, fatigue, headache, myalgias, general lethargy, body ache, arthralgia, nausea, chills, fever, and dizziness. The overall mean efficiency for the prevention of the COVID-19 disease is 73.78% for Sinopharm, 70.96% for CoronaVac, and 61.80% for Covaxin. In conclusion, all three inactivated whole-virus COVID-19 vaccines, Sinopharm, CoronaVac, and Covaxin, are beneficial for the prevention of the COVID-19 pandemic. However, evidence suggests that the overall impact of Sinopharm is slightly better than that of CoronaVac and Covaxin.

Keywords: SARS-CoV-2; adverse effects; pharmacology; vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram for the selection of fact sheets and documents about Sinopharm, CoronaVac, and Covaxin COVID-19 vaccines.
Figure 2
Figure 2
Distribution of studies selected for the efficacy of the Sinopharm, CoronaVac, and Covaxin vaccines for the prevention of COVID-19 [10,11,14,15,29,30,31,32,34,35,36,37,40,41,42,43,44,47,48,49].
Figure 3
Figure 3
Efficacy of the Sinopharm, CoronaVac, and Covaxin vaccines for the prevention of COVID-19 [29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Meo S.A., Alsomali A.H., Almushawah A.A., Halepoto D.M. Seasonal variations impact on SARS-CoV-2 incidence and mortality in southern and northern hemispheres: Two years pandemic period-based study. J. King Saud Univ. Sci. 2022;34:102335. doi: 10.1016/j.jksus.2022.102335. - DOI - PMC - PubMed
    1. World Health Organization (WHO) WHO Coronavirus (COVID-19) Dashboard. [(accessed on 25 March 2023)]. Available online: https://covid19.who.int/
    1. Centres for Disease Control and Prevention (CDC) Scientific Brief: SARS-CoV-2. Transmission. [(accessed on 23 January 2023)]; Available online: https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-co.... - PubMed
    1. Meyerowitz E.A., Richterman A., Gandhi R.T., Sax P.E. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Ann. Intern. Med. 2021;174:69–79. doi: 10.7326/M20-5008. - DOI - PMC - PubMed
    1. World Health Organization (WHO) Getting the COVID-19 Vaccine. [(accessed on 23 January 2023)]. Available online: https://www.who.int/news-room/feature-stories/detail/getting-the-covid-1....

LinkOut - more resources